NASDAQ$FLNA
Filana Therapeutics Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Announced financial results for the year ended December 31, 2022, and provided operating updates.
Cassava Sciences reported financial results for the year ended December 31, 2022, and provided operating updates.
- Over 1,000 patients with Alzheimer’s are now enrolled in Phase 3 studies.
- Expect to reach enrollment target of approximately 1,750 patients for the Phase 3 studies by year-end 2023.
- Top-line results for an open-label study showed Simufilam was well-tolerated, with 47% of patients improving on ADAS-Cog scores over 12 months and an additional 23% declining less than 5 points on ADAS-Cog.
- Cassava Sciences is currently evaluating simufilam tablets for Alzheimer’s disease dementia in two Phase 3 clinical studies.
Headline financials
Revenue & EPS history
Cassava Sciences · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
+0.3%
Avg return
Earnings day
+1.0%
Avg return
5 days after
-5.1%
Avg return
30 days after
40%
23 / 57 earnings
Positive
+16.1%
Q4 2013
Best reaction
-12.6%
Q3 2014
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -0.5% | -16.7% | -9.0% | |
| Q3 2025 | +5.2% | -10.6% | -5.8% | |
| Q2 2025 | +5.3% | -3.9% | -7.5% | |
| Q1 2025 | -1.0% | +1.4% | -1.9% | |
| Q4 2024 | +3.3% | +17.1% | -42.1% | |
| Q3 2024 | +1.3% | -0.7% | -87.9% | |
| Q1 2024 | -2.3% | +9.0% | -7.0% | |
| Q4 2023 | -0.3% | -2.1% | -11.8% | |
| Q3 2023 | +3.3% | -8.2% | -2.8% | |
| Q2 2023 | -4.0% | -10.5% | +0.3% | |
| Q1 2023 | -4.5% | -3.9% | -2.2% | |
| Q4 2022 | +0.8% | +6.9% | -3.1% | |
| Q3 2022 | -1.2% | +6.6% | +4.6% | |
| Q2 2022 | -11.6% | +0.2% | +27.3% | |
| Q1 2022 | -5.3% | -6.3% | +37.7% | |
| Q4 2021 | -5.4% | -12.2% | -9.3% | |
| Q3 2021 | -7.6% | -22.8% | -43.8% | |
| Q2 2021 | +10.3% | +20.5% | -32.0% | |
| Q1 2021 | +12.2% | +30.0% | +55.6% | |
| Q4 2020 | -12.5% | -16.6% | -35.4% | |
| Q3 2020 | -6.5% | -21.8% | -26.4% | |
| Q2 2020 | +9.9% | +20.9% | +13.7% | |
| Q1 2020 | +0.0% | +22.8% | -67.0% | |
| Q4 2019 | +2.6% | -1.0% | +71.6% | |
| Q3 2019 | +4.7% | +3.1% | +13.4% | |
| Q2 2019 | -7.5% | -6.8% | -4.5% | |
| Q1 2019 | -2.7% | -5.3% | +1.8% | |
| Q4 2018 | -4.1% | +6.6% | -6.6% | |
| Q3 2018 | -4.1% | +0.0% | -9.0% | |
| Q2 2018 | -0.4% | +1.4% | -56.6% | |
| Q1 2018 | +12.1% | +11.5% | +26.4% | |
| Q4 2017 | -5.6% | -1.9% | +11.4% | |
| Q3 2017 | -2.6% | +3.4% | +15.0% | |
| Q2 2017 | -4.7% | +0.3% | -4.4% | |
| Q1 2017 | +2.6% | +10.4% | -19.1% | |
| Q4 2016 | +0.0% | +0.0% | +18.6% | |
| Q3 2016 | +15.4% | -1.5% | -7.7% | |
| Q2 2016 | +5.8% | +17.9% | +12.9% | |
| Q1 2016 | +3.4% | — | — | |
| Q4 2015 | +9.2% | — | — | |
| Q3 2015 | +0.0% | — | — | |
| Q2 2015 | +0.0% | — | — | |
| Q1 2015 | +0.0% | — | — | |
| Q4 2014 | -4.4% | — | — | |
| Q3 2014 | -12.6% | — | — | |
| Q2 2014 | -4.0% | — | — | |
| Q1 2014 | -3.7% | — | — | |
| Q4 2013 | +16.1% | — | — | |
| Q3 2013 | -4.4% | — | — | |
| Q2 2013 | -4.1% | — | — | |
| Q1 2013 | +3.8% | — | — | |
| Q4 2012 | +3.9% | — | — | |
| Q4 2011 | -1.9% | — | — | |
| Q1 2011 | +3.6% | — | — | |
| Q3 2010 | +5.4% | — | — | |
| Q2 2010 | +9.1% | — | — | |
| Q1 2010 | -1.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro